Personalized Translational Platform for Biomarker Discovery in Brain Tumors
Completed
- Conditions
- High Grade Glioma
- Registration Number
- NCT01240161
- Lead Sponsor
- Marcelo F. Di Carli, MD, FACC
- Brief Summary
The central hypothesis for this proposal is that multimodal (clinical, imaging, tissue) biomarkers will better predict early brain tumor response to treatments and will be more reliable prognostic markers in patients with malignant brain tumors.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 37
Inclusion Criteria
- Newly diagnosed or suspected high grade glioma ≥ 1cm in diameter on postoperative anatomic imaging (contrast MRI), prior to initiation of chemoXRT
- Anticipated survival ≥6 months
- Able to give informed consent
- Capable of undergoing MRI and PET scans without the need for sedation or general anesthesia
- Male or Female
Exclusion Criteria
- Prior radiation therapy and chemotherapy to the brain
- Active intracranial infection or nonglial brain mass.
- Recent large intracranial hemorrhage (<1 month)
- Expected survival <6 months
- Pregnant or nursing
- Renal failure
- Lives far from BWH and/or is unwilling/ unable to return for scheduled imaging visits.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Overall Survival 7 months Progression free Survival 7 months MRI and clinical criteria
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (2)
University of California at San Diego
🇺🇸San Diego, California, United States
Brigham and Women's Hospital
🇺🇸Boston, Massachusetts, United States